{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093237","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.322925+00:00","generated_at":"2026-05-31T11:21:33.852628+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CG Oncology Q2 net loss $18.9M; cash $552.9M; positive CORE-001 combo data published in Nature Medicine","bullets":["Net loss of $18.9M ($0.28 EPS) vs $11.6M loss ($3.93 EPS) in Q2 2023; R&D spend $18.5M vs $9.8M YoY.","Cash, equivalents and marketable securities $552.9M as of June 30, 2024; runway expected through 2027.","CORE-001 (cretostimogene + pembrolizumab) achieved 54% complete response at 24 months; 100% progression-free survival at 24 months.","BOND-003 monotherapy showed 75.2% CR at any time (n=105); no Grade 3+ AEs or treatment-related discontinuations.","Expanded Access Program initiated first patient dosed in June; primary BOND-003 results expected by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093237","json":"https://secwatch.observer/filing/0000950170-24-093237.json","markdown":"https://secwatch.observer/filing/0000950170-24-093237.md","text":"https://secwatch.observer/filing/0000950170-24-093237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000095017024093237/0000950170-24-093237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000095017024093237/ck0001991792-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:21:33.852628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}